MAY 14·MoomooMed
Allogene Therapeutics Q1 Net Loss Narrows
NULL
StockHealthcare · Biotechnology
$ALLO
Allogene Therapeutics, Inc.
Price · $ALLOvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ALLO in the last 7 days.
Insider · 30dFeed →
No SEC Form 4 filings for $ALLO in the last 30 days.
Top stories · $ALLOMore →
APR 16·StocksToTrade
ALLO Stock Slumps As $175M Secondary Offering Hits Tape
Allogene Therapeutics (ALLO) stock slumped by 16.01% after announcing a $175M underwritten public offering of 87.5 million shares at $2.00 per share, significantly diluting existing shareholders. The offering, designed to fund clinical trials and R&D for its CAR-T pipeline, led to an 18% intraday price drop on increased volume. Traders are closely monitoring ALLO due to the dilution, insider selling intentions, and its high-burn, high-volatility biotech profile.
APR 10·GlobeNewswire
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Allogene Therapeutics, Inc. announced it will host a conference call and webcast on Monday, April 13, 2026, to review interim futility analysis data from its pivotal Phase 2 ALPHA3 trial. This trial evaluates cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL). The company, a clinical-stage biotechnology firm, specializes in developing allogeneic CAR T products for cancer and autoimmune diseases.